• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Galapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some Caveats

cafead

Administrator
Staff member
  • cafead   Aug 26, 2024 at 11:32: AM
via Galapagos (GLPG) stock surged Monday after the Food and Drug Administration cleared the biotech company to begin testing its cancer drug in people. RBC Capital Markets analyst Brian Abrahams says this is an important step for furthering Galapagos' point-of-care model for CAR-T drugs. CAR-T drugs involve removing a patient's immune cells and then genetically modifying them to find and destroy cancer cells.

article source
 

<